Boston Scientific Corporation
Case Overview
55 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 05/04/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Boston Scientific Corporation |
| Court: | Court: District of Massachusetts |
| Case Number: | Case Number: 4:26cv40075 |
| Class Period: | Class Period: 07/23/2025 - 02/03/2026 |
| Ticker: | Ticker: BSX |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE:BSX) securities during the period of July 23, 2025 through February 3, 2026, inclusive (“the Class Period”).
According to the complaint, the Company provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Boston Scientific's U.S. EP segment; notably, that management was aware that the segment's growth rate was unsustainable and that it was approaching an earlier tipping point than the market was anticipating. Due to defendants' statements of confidence and lofty expectations, investors and analysts were left surprised by Boston Scientific's net income miss and underwhelming guidance for the first half of fiscal 2026.
On February 4, 2026, Boston Scientific published a press release announcing fourth quarter and full year 2025 results, including a pertinent disappointment in U.S. EP sales, and issued guidance for fiscal 2026. The Company attributed its results and guidance on a combination of slower than expected market growth alongside increased competition, despite management's previous claims of a "growing" EP business and assertions they "have a very good understanding of what competition we will face and in what time frame." On this news, the price of Boston Scientific shares declined by $16.12 per share, or approximately 17.6%, from $91.62 per share on February 3, 2026 to close at $75.50 on February 4, 2026.
According to the complaint, the Company provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Boston Scientific's U.S. EP segment; notably, that management was aware that the segment's growth rate was unsustainable and that it was approaching an earlier tipping point than the market was anticipating. Due to defendants' statements of confidence and lofty expectations, investors and analysts were left surprised by Boston Scientific's net income miss and underwhelming guidance for the first half of fiscal 2026.
On February 4, 2026, Boston Scientific published a press release announcing fourth quarter and full year 2025 results, including a pertinent disappointment in U.S. EP sales, and issued guidance for fiscal 2026. The Company attributed its results and guidance on a combination of slower than expected market growth alongside increased competition, despite management's previous claims of a "growing" EP business and assertions they "have a very good understanding of what competition we will face and in what time frame." On this news, the price of Boston Scientific shares declined by $16.12 per share, or approximately 17.6%, from $91.62 per share on February 3, 2026 to close at $75.50 on February 4, 2026.